Author: Damora Therapeutics, Inc.

Posted Date:

March 30, 2026

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics, Inc.

March 30, 2026
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

Damora Therapeutics, Inc.

March 23, 2026
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Damora Therapeutics, Inc.

March 19, 2026